The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $0.27 in the prior trading day, Carisma Therapeutics Inc (NASDAQ: CARM) closed at $0.26, down -3.37%. In other words, the price has decreased by -$3.37 from its previous closing price. On the day, 1.3 million shares were traded. CARM stock price reached its highest trading level at $0.2699 during the session, while it also had its lowest trading level at $0.2588.
Ratios:
Our goal is to gain a better understanding of CARM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.48 and its Current Ratio is at 0.48.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on December 12, 2024, Downgraded its rating to Neutral and sets its target price to $1 from $10 previously.
On April 11, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on April 11, 2024, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 02 ’25 when Klichinsky Michael sold 200,000 shares for $0.25 per share. The transaction valued at 50,860 led to the insider holds 119,347 shares of the business.
Klichinsky Michael sold 165,000 shares of CARM for $42,405 on Oct 01 ’25. The Chief Scientific Officer now owns 319,347 shares after completing the transaction at $0.26 per share. On Oct 03 ’25, another insider, Klichinsky Michael, who serves as the Chief Scientific Officer of the company, sold 119,347 shares for $0.26 each. As a result, the insider received 31,078 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CARM now has a Market Capitalization of 10902514 and an Enterprise Value of 10603514. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.01. Its current Enterprise Value per Revenue stands at 0.985 whereas that against EBITDA is -0.252.
Stock Price History:
The Beta on a monthly basis for CARM is 2.06, which has changed by -0.72322375 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, CARM has reached a high of $1.27, while it has fallen to a 52-week low of $0.14. The 50-Day Moving Average of the stock is -13.61%, while the 200-Day Moving Average is calculated to be -25.32%.
Shares Statistics:
The stock has traded on average 8.53M shares per day over the past 3-months and 967050 shares per day over the last 10 days, according to various share statistics. A total of 41.79M shares are outstanding, with a floating share count of 24.89M. Insiders hold about 40.44% of the company’s shares, while institutions hold 4.29% stake in the company. Shares short for CARM as of 1757894400 were 1568689 with a Short Ratio of 0.18, compared to 1755216000 on 560927. Therefore, it implies a Short% of Shares Outstanding of 1568689 and a Short% of Float of 4.33.
Earnings Estimates
The stock of Carisma Therapeutics Inc (CARM) is currently drawing attention from 1.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.12 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.69 and -$0.69 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is -$0.52, with 1.0 analysts recommending between -$0.52 and -$0.52.
